Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?

Lancet Oncol. 2019 Nov;20(11):1473-1474. doi: 10.1016/S1470-2045(19)30619-9. Epub 2019 Sep 25.

Authors

Sumanta Pal¹, Siwen Hu-Lieskovan², Neeraj Agarwal²

Affiliations

¹ Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA. Electronic address: spal@coh.org.
² Division of Medical Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.

PMID: 31563518
DOI: 10.1016/S1470-2045(19)30619-9

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Interleukin-10*
Neoplasms*
Nivolumab
Polyethylene Glycols
Programmed Cell Death 1 Receptor

Substances

Antibodies, Monoclonal, Humanized
Programmed Cell Death 1 Receptor
pegilodecakin
Interleukin-10
Nivolumab
Polyethylene Glycols
pembrolizumab